Convert HbA1c between NGSP (%) and IFCC (mmol/mol), estimate average glucose, and review broad diabetes threshold context.
Hemoglobin A1c (HbA1c) is a standard laboratory measure used to summarize average glucose exposure over roughly the previous 2–3 months. It reports the percentage of hemoglobin that has been glycated during red-cell turnover and is commonly used alongside fasting glucose, oral glucose tolerance testing, or continuous glucose data.
This page converts between the NGSP/DCCT percentage format used in the United States and the IFCC mmol/mol format used internationally. It also translates HbA1c into estimated average glucose (eAG) with the ADAG equation and places the result next to broad diagnostic threshold bands.
The result is a structured reference aid, not a personalized diabetes-management engine. HbA1c can read artificially high or low in settings such as anemia, hemoglobin variants, recent transfusion, kidney disease, pregnancy, or altered red-cell turnover, so interpretation still depends on the broader clinical picture.
This calculator keeps the most common HbA1c reference tasks together: NGSP/IFCC conversion, estimated average glucose, and broad threshold context. That makes it useful for reading lab results and comparing formats without turning the page into a treatment protocol.
IFCC (mmol/mol) = (NGSP % − 2.15) × 10.929. eAG (mg/dL) = 28.7 × HbA1c − 46.7. eAG (mmol/L) = eAG (mg/dL) ÷ 18.0182.
Result: eAG = 169 mg/dL (9.4 mmol/L), IFCC = 58 mmol/mol, Diabetes range
An HbA1c of 7.5% converts to 58 mmol/mol and an estimated average glucose of about 169 mg/dL. The page uses that conversion to place the result in broad threshold context rather than to prescribe a treatment target.
HbA1c is reported in two common formats: NGSP/DCCT percent and IFCC mmol/mol. Converting between those systems is useful when comparing U.S. and international lab reports or reading guideline tables that use different units.
Estimated average glucose is useful because many people understand glucose units more intuitively than percentages. It provides a bridge between laboratory HbA1c reporting and the glucose values seen on home monitoring or CGM summaries.
HbA1c is not perfect. Anemia, hemoglobin variants, pregnancy, kidney disease, recent transfusion, and altered red-cell lifespan can all make the result look higher or lower than the true glucose pattern. When that possibility exists, HbA1c should be read with the rest of the diabetes workup rather than by itself.
Last updated:
This page converts HbA1c between NGSP/DCCT percent and IFCC mmol/mol, then uses the ADAG equation to estimate average glucose in mg/dL and mmol/L. It also compares the entered value with broad diabetes threshold bands and shows a simple fasting-glucose concordance note when an optional fasting value is entered.
The result is a structured reference aid, not an individualized diabetes-management engine. HbA1c can be misleading in settings such as anemia, hemoglobin variants, pregnancy, kidney disease, recent transfusion, or altered red-cell lifespan, so interpretation still depends on the broader clinical picture.
A normal HbA1c is below 5.7% (39 mmol/mol). Between 5.7% and 6.4% is classified as pre-diabetes. At 6.5% or above on two separate tests, diabetes is diagnosed per ADA guidelines.
HbA1c reflects average glucose over 2-3 months. An A1c of 7% corresponds to approximately 154 mg/dL (8.6 mmol/L) using the validated ADAG equation.
Meter readings often capture only a few parts of the day, while HbA1c reflects the broader 2–3 month picture. Discordance can also happen with anemia, hemoglobin variants, kidney disease, pregnancy, recent transfusion, or other changes in red-cell turnover.
NGSP (National Glycohemoglobin Standardization Program) reports in %, while IFCC (International Federation of Clinical Chemistry) reports in mmol/mol. The US primarily uses NGSP; Europe and much of the world uses IFCC.
HbA1c may be unreliable with hemoglobin variants (HbS, HbC, HbE). Some assays are affected differently. Alternatives include fructosamine, glycated albumin, and continuous glucose monitoring.
Testing frequency depends on diagnosis, treatment changes, and how stable the glucose pattern is. The right interval should come from the clinician managing the diabetes workup or treatment plan.
No. It shows broad threshold context and a common reference goal used in many adults, but personal goals vary with age, pregnancy, medication risks, comorbidities, and the overall treatment plan.